JAK Inhibition in Aicardi-Goutières Syndrome : a Monocentric Multidisciplinary Real-World Approach Study
© 2023. The Author(s)..
The paradigm type I interferonopathy Aicardi-Goutières syndrome (AGS) is most typically characterized by severe neurological involvement. AGS is considered an immune-mediated disease, poorly responsive to conventional immunosuppression. Premised on a chronic enhancement of type I interferon signaling, JAK1/2 inhibition has been trialed in AGS, with clear improvements in cutaneous and systemic disease manifestations. Contrastingly, treatment efficacy at the level of the neurological system has been less conclusive. Here, we report our real-word approach study of JAK1/2 inhibition in 11 patients with AGS, providing extensive assessments of clinical and radiological status; interferon signaling, including in cerebrospinal fluid (CSF); and drug concentrations in blood and CSF. Over a median follow-up of 17 months, we observed a clear benefit of JAK1/2 inhibition on certain systemic features of AGS, and reproduced results reported using the AGS neurologic severity scale. In contrast, there was no change in other scales assessing neurological status; using the caregiver scale, only patient comfort, but no other domain of everyday-life care, was improved. Serious bacterial infections occurred in 4 out of the 11 patients. Overall, our data lead us to conclude that other approaches to treatment are urgently required for the neurologic features of AGS. We suggest that earlier diagnosis and adequate central nervous system penetration likely remain the major factors determining the efficacy of therapy in preventing irreversible brain damage, implying the importance of early and rapid genetic testing and the consideration of intrathecal drug delivery.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Journal of clinical immunology - 43(2023), 6 vom: 12. Aug., Seite 1436-1447 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Aicardi-Goutières syndrome (AGS) |
|---|
| Anmerkungen: |
Date Completed 21.07.2023 Date Revised 21.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10875-023-01500-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356745961 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356745961 | ||
| 003 | DE-627 | ||
| 005 | 20231226071123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10875-023-01500-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM356745961 | ||
| 035 | |a (NLM)37171742 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Frémond, Marie-Louise |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a JAK Inhibition in Aicardi-Goutières Syndrome |b a Monocentric Multidisciplinary Real-World Approach Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2023 | ||
| 500 | |a Date Revised 21.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a The paradigm type I interferonopathy Aicardi-Goutières syndrome (AGS) is most typically characterized by severe neurological involvement. AGS is considered an immune-mediated disease, poorly responsive to conventional immunosuppression. Premised on a chronic enhancement of type I interferon signaling, JAK1/2 inhibition has been trialed in AGS, with clear improvements in cutaneous and systemic disease manifestations. Contrastingly, treatment efficacy at the level of the neurological system has been less conclusive. Here, we report our real-word approach study of JAK1/2 inhibition in 11 patients with AGS, providing extensive assessments of clinical and radiological status; interferon signaling, including in cerebrospinal fluid (CSF); and drug concentrations in blood and CSF. Over a median follow-up of 17 months, we observed a clear benefit of JAK1/2 inhibition on certain systemic features of AGS, and reproduced results reported using the AGS neurologic severity scale. In contrast, there was no change in other scales assessing neurological status; using the caregiver scale, only patient comfort, but no other domain of everyday-life care, was improved. Serious bacterial infections occurred in 4 out of the 11 patients. Overall, our data lead us to conclude that other approaches to treatment are urgently required for the neurologic features of AGS. We suggest that earlier diagnosis and adequate central nervous system penetration likely remain the major factors determining the efficacy of therapy in preventing irreversible brain damage, implying the importance of early and rapid genetic testing and the consideration of intrathecal drug delivery | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Aicardi-Goutières syndrome (AGS) | |
| 650 | 4 | |a JAK inhibitors | |
| 650 | 4 | |a interferon | |
| 700 | 1 | |a Hully, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Fournier, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Barrois, Rémi |e verfasserin |4 aut | |
| 700 | 1 | |a Lévy, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Aubart, Mélodie |e verfasserin |4 aut | |
| 700 | 1 | |a Castelle, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Chabalier, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Gins, Clarisse |e verfasserin |4 aut | |
| 700 | 1 | |a Sarda, Eugénie |e verfasserin |4 aut | |
| 700 | 1 | |a Al Adba, Buthaina |e verfasserin |4 aut | |
| 700 | 1 | |a Couderc, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a D' Almeida, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Berat, Claire-Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Durrleman, Chloé |e verfasserin |4 aut | |
| 700 | 1 | |a Espil, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Lambert, Laetitia |e verfasserin |4 aut | |
| 700 | 1 | |a Méni, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Périvier, Maximilien |e verfasserin |4 aut | |
| 700 | 1 | |a Pillet, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Polivka, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Schiff, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Todosi, Calina |e verfasserin |4 aut | |
| 700 | 1 | |a Uettwiller, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Lepelley, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Rice, Gillian I |e verfasserin |4 aut | |
| 700 | 1 | |a Seabra, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Sanquer, Sylvia |e verfasserin |4 aut | |
| 700 | 1 | |a Hulin, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Pressiat, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Goldwirt, Lauriane |e verfasserin |4 aut | |
| 700 | 1 | |a Bondet, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Duffy, Darragh |e verfasserin |4 aut | |
| 700 | 1 | |a Moshous, Despina |e verfasserin |4 aut | |
| 700 | 1 | |a Bader-Meunier, Brigitte |e verfasserin |4 aut | |
| 700 | 1 | |a Bodemer, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Robin-Renaldo, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Boddaert, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Blanche, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Desguerre, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Crow, Yanick J |e verfasserin |4 aut | |
| 700 | 1 | |a Neven, Bénédicte |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical immunology |d 1981 |g 43(2023), 6 vom: 12. Aug., Seite 1436-1447 |w (DE-627)NLM012677426 |x 1573-2592 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:6 |g day:12 |g month:08 |g pages:1436-1447 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10875-023-01500-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 6 |b 12 |c 08 |h 1436-1447 | ||